Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids

The problem with repurposing: Is there really an alternative to Big Pharma for developing new drugs for multiple sclerosis?

(2015) Gavin Giovannoni et al.   Multiple Sclerosis and Related Disorders

Nonpsychotropic Plant Cannabinoids, Cannabidivarin (CBDV) and Cannabidiol (CBD), Activate and Desensitize Transient Receptor Potential Vanilloid 1 (TRPV1) Channels in Vitro: Potential for the Treatment of Neuronal Hyperexcitability

(2014) Fabio Arturo Iannotti et al.   ACS Chemical Neuroscience

A Reversible and Selective Inhibitor of Monoacylglycerol Lipase Ameliorates Multiple Sclerosis

(2014) Gloria Hernández-Torres et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Blockade of monoacylglycerol lipase inhibits oligodendrocyte excitotoxicity and prevents demyelinationin vivo

(2014) Ana Bernal-Chico et al.   GLIA

Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis: Report of the Guideline Development Subcommittee of the American Academy of Neurology

(2014) V. Yadav et al.   NEUROLOGY

Pre- and postsynaptic type-1 cannabinoid receptors control the alterations of glutamate transmission in experimental autoimmune encephalomyelitis

(2014) Alessandra Musella et al.   NEUROPHARMACOLOGY

Voltage-gated sodium (NaV) channel blockade by plant cannabinoids does not confer anticonvulsant effects per se

(2014) Andrew J. Hill et al.   NEUROSCIENCE LETTERS

Association between a Genetic Variant of Type-1 Cannabinoid Receptor and Inflammatory Neurodegeneration in Multiple Sclerosis

(2014) Silvia Rossi et al.   PLoS One

Experimental autoimmune encephalomyelitis is a good model of multiple sclerosis if used wisely

(2014) David Baker et al.   Multiple Sclerosis and Related Disorders

Cannabis use by individuals with multiple sclerosis: effects on specific immune parameters

(2014) Michelle Sexton et al.   INFLAMMOPHARMACOLOGY

Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis

(2013) Sarah Al-Izki et al.   BRAIN

Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis

(2013) Damineh Morsali et al.   BRAIN

Control of spasticity in a multiple sclerosis model using central nervous system-excluded CB1 cannabinoid receptor agonists

(2013) Gareth Pryce et al.   FASEB JOURNAL

Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial

(2013) John Zajicek et al.   LANCET NEUROLOGY

Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors

(2013) M. Mecha et al.   NEUROBIOLOGY OF DISEASE

Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors

(2013) Francisco Espejo-Porras et al.   NEUROPHARMACOLOGY

Therapeutic potential of a novel cannabinoid agent CB52 in the mouse model of experimental autoimmune encephalomyelitis

(2013) R. Ribeiro et al.   NEUROSCIENCE

Biomarker Report from the Phase II Lamotrigine Trial in Secondary Progressive MS – Neurofilament as a Surrogate of Disease Progression

(2013) Sharmilee Gnanapavan et al.   PLoS One

Genetic Background Can Result in a Marked or Minimal Effect of Gene Knockout (GPR55 and CB2 Receptor) in Experimental Autoimmune Encephalomyelitis Models of Multiple Sclerosis

(2013) Sofia Sisay et al.   PLoS One

Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial

(2012) J. Corey-Bloom et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis

(2012) R. M. Langford et al.   JOURNAL OF NEUROLOGY

Δ9-tetrahydrocannabinol (Δ9-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease

(2012) C. B. Carroll et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects

(2012) Eva de Lago et al.   NEUROPHARMACOLOGY

Cannabidiol protects oligodendrocyte progenitor cells from inflammation-induced apoptosis by attenuating endoplasmic reticulum stress

(2012) M Mecha et al.   Cell Death & Disease

The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis

(2012) David Baker et al.   Multiple Sclerosis and Related Disorders

Cannabinoid CB1 receptors regulate neuronal TNF-α effects in experimental autoimmune encephalomyelitis

(2011) Silvia Rossi et al.   BRAIN BEHAVIOR AND IMMUNITY

Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice

(2011) Ewa Kozela et al.   BRITISH JOURNAL OF PHARMACOLOGY

Heterogeneity in the composition of marijuana seized in California

(2011) James Richard Burgdorf et al.   DRUG AND ALCOHOL DEPENDENCE

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis

(2011) A. Novotna et al.   EUROPEAN JOURNAL OF NEUROLOGY

CB1 receptor antagonism/inverse agonism increases motor system excitability in humans

(2011) A. Oliviero et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Publication guidelines for refereeing and reporting on animal use in experimental autoimmune encephalomyelitis

(2011) David Baker et al.   JOURNAL OF NEUROIMMUNOLOGY

Critical appraisal of animal models of multiple sclerosis

(2011) David Baker et al.   Multiple Sclerosis Journal

Practical guide to the induction of relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouse

(2011) Sarah Al-Izki et al.   Multiple Sclerosis and Related Disorders

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab

(2010) Martin Gunnarsson et al.   ANNALS OF NEUROLOGY

Evidence for a two-stage disability progression in multiple sclerosis

(2010) E. Leray et al.   BRAIN

Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial

(2010) Raju Kapoor et al.   LANCET NEUROLOGY

The (AAT)n repeat of the cannabinoid CB1 receptor gene influences disease progression in relapsing multiple sclerosis

(2010) Silvia Rossi et al.   Multiple Sclerosis Journal

Neuroprotection without Immunomodulation Is Not Sufficient to Reduce First Relapse Severity in Experimental Autoimmune Encephalomyelitis

(2010) Henrik Hasseldam et al.   NEUROIMMUNOMODULATION

Cannabidiol Targets Mitochondria to Regulate Intracellular Ca2+ Levels

(2009) D. Ryan et al.   JOURNAL OF NEUROSCIENCE

A role for CB2 receptors in anandamide signalling pathways involved in the regulation of IL-12 and IL-23 in microglial cells

(2008) Fernando Correa et al.   BIOCHEMICAL PHARMACOLOGY

Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Δ9-tetrahydrocannabinol

(2008) Robert E. Vann et al.   DRUG AND ALCOHOL DEPENDENCE

Multiple sclerosis

(2008) Alastair Compston et al.   LANCET

Genetic deletion of Fatty Acid Amide Hydrolase results in improved long-term outcome in chronic autoimmune encephalitis

(2008) Michael Webb et al.   NEUROSCIENCE LETTERS

Control of Spasticity in a Multiple Sclerosis Model is mediated by CB1, not CB2, Cannabinoid Receptors

(2007) G Pryce et al.   BRITISH JOURNAL OF PHARMACOLOGY

Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro

(2007) A Thomas et al.   BRITISH JOURNAL OF PHARMACOLOGY

Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis

(2007) J. Ludovic Croxford et al.   JOURNAL OF NEUROIMMUNOLOGY